SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors react to the company's annual shareholder meeting and news regarding a potential acquisition of eBay, sparking intense debate over whether these developments signal a strategic pivot or further dilution. The community remains deeply divided, with bulls highlighting long-term turnaround efforts while bears and frustrated retail holders point to stagnant price action and past failed squeeze predictions.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is seeing heightened activity as the community debates whether recent competitive headlines and sector volatility signal a structural threat or a temporary accumulation opportunity. Traders remain fixated on the stock's ability to reclaim the $200 level, with many viewing the ongoing price consolidation as a test of conviction amidst the broader AI infrastructure arms race.

Vera Therapeutics, Inc. is a clinical stage biotechnical company which engages in the development and commercialization of transformative treatments for immunological diseases. The company was founded by Marshall Fordyce in May 2016 and is headquartered in Brisbane, CA.

Vera Therapeutics Inc - Ordinary Shares - Class A

Vera Therapeutics is trending as investors react to a significant clinical data milestone regarding the stabilization of kidney function for its lead drug, Atacicept, alongside optimism surrounding its regulatory pathway. The community is actively debating the stock's potential for a short squeeze due to high short interest, while institutional investors closely monitor its competitive positioning in the IgA nephropathy market.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian shares are under pressure after the company announced a 75 million-share offering to fund its U.S. Department of Energy loan obligations, sparking a heated debate between long-term investors focused on growth and traders concerned about shareholder dilution. While some community members view the capital raise as a necessary step for production scaling, others are actively criticizing the timing of the offering and the resulting impact on the stock's recent momentum.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Arbutus Biopharma Corp

Arbutus Biopharma is currently capturing investor attention following the FDA's decision to grant fast track designation to its lead chronic Hepatitis B candidate, imdusiran. The community is actively debating the stock's long-term valuation in light of this clinical progress, alongside ongoing patent litigation catalysts against major pharmaceutical firms and potential strategic takeover interest.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. It will generate domestically produced bitcoin powered by nuclear, hydro, and solar energy. It operates through the Digital Asset Mining and HPC Leasing segments. The company was founded by Paul B. Prager and Nazar M. Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf is trending following a massive 20-year, 401-megawatt lease agreement with Anthropic for its Kentucky data center campus, which management describes as only the beginning of a broader AI infrastructure push. The community is intensely debating the deal's long-term revenue potential versus ongoing stock price volatility, with many users focused on whether the announcement justifies a significant valuation re-rating or if the sector remains hindered by broader market manipulation and short-term profit-taking.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as investors speculate on a potential buyout, fueled by the company's strong commercial growth, label expansion efforts into indications like myasthenia gravis and schizophrenia, and expectations for the upcoming subcutaneous Briumvi rollout. The community is actively discussing bullish price action, recent institutional accumulation, and the belief that the stock remains undervalued compared to peers, keeping M&A sentiment high.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Viking Therapeutics is gaining momentum as investors anticipate upcoming maintenance trial data, fueling speculation about a potential buyout or major partnership with pharmaceutical giants. Community discussions are centered on the stock's long-term value relative to sector leaders, with many bulls actively bracing for a potential short squeeze as institutional accumulation continues.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. Its products include Gvoke, Keveyis, and Recorlev. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending as investors react to a solid earnings report and raised revenue guidance, fueling community speculation about a potential buyout or major partnership as the company approaches self-sustainability. Discussions remain heavily focused on the blockbuster potential of Recorlev and the upcoming Phase 3 development of their once-weekly injectable levothyroxine candidate, XP-8121.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is gaining significant investor attention as recent Phase 3 data and potential FDA approval milestones for its lead psychedelic program, COMP360, strengthen the company's commercial outlook for treatment-resistant depression. Community discussion is heavily focused on the stock's role as a first-mover in a nascent sector, with many participants tracking institutional interest, the upcoming NDA submission, and the potential for a transformative impact on psychiatric medicine.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Medpace Growth Trends Show How CRO Demand Is Shifting in 2026

MEDP's 2026 outlook highlights shifting CRO demand, longer award-to-revenue timing and steady margins, while AI investment delays near-term productivity gains.

ICON Stock Outlook 2026 as Margin Woes Meet a Stronger Backlog Base

ICON's stronger bookings and backlog hint at improving demand, but margin pressure, earnings declines and control remediation keep 2026 cautious.

Medpace Stock Outlook Turns on Backlog Quality and Cancellations

MEDP's outlook hinges on whether strong backlog quality and metabolic demand can offset rising cancellations and softer proposal activity.

Here's Why Investors Should Hold IQV Stock in Their Portfolios Now

IQVIA's AI tools, record R&D backlog and strong free cash flow support its outlook, but weak liquidity and no dividend remain investor concerns.

IQVIA Holdings Moves Up In Market Cap Rank, Passing Atmos Energy

In the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, IQVIA Holdings Inc (Symbol: IQV) has taken over the #311 spot from Atmos Energy Corp. (Symbol: ATO), according to The Online Investor.

 Market capitalization is an imp...

Why IQVIA Holdings (IQV) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Global Healthcare Infrastructure Strengthens IQV Amid Weak Liquidity

IQVIA Holdings gains from its vast healthcare data, AI-driven analytics & global IT infrastructure, supporting expansion and solid growth.

Here's Why IQVIA Holdings (IQV) is a Strong Momentum Stock

Wiley and IQVIA Release Cross-Sector Report on AIs Promise and Pressure Points Across Healthcare Value Chain

Wiley (NYSE: WLY) and IQVIA (NYSE: IQV) today released Scientific Discovery & AI: The Science-to-Patient Journey, a cross-sector intelligence report drawing on candid dialogue among more than 25 senior leaders from pharma R&D, academic medicine, health systems, AI and technology, publishing and...

ICON Stock Valuation vs Peers: Is ICLR Cheap Enough?

ICLR looks cheap at 14.7x forward EPS versus peers, but 2026 guidance calls for lower revenue/EPS and a weak margin starting point.

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. It operates through the following segments: Technology and Analytics Solutions, Research and Development Solutions, and Contract Sales and Medical Solutions. The Technology and Analytics Solutions segment supplies mission-critical information, technology solutions, and real-world evidence services to the company's life sciences clients. The Research and Development Solutions segment provides outsourced clinical research and clinical trial-related services. The Contract Sales and Medical Solutions segment offers healthcare provider and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company was founded by Dennis B. Gillings and Gary Koch in 1950 and is headquartered in Durham, NC.

IQVIA Holdings Inc

Retail Raves About IQVIA Holdings After Firm Raises Revenue, Profit Guidance

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

IQVIQVIA Holdings Inc

Latest IQV News